IJGC Podcast

Reviewing the January Issue with Florencia Noll (Spanish Version)

In this episode of the IJGC Podcast, Florencia Noll discusses the contents of the January issue of IJGC in Spanish.

Asbestos and Ovarian Cancer with Brian Slomovitz

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Brian Slomovitz to discuss asbestos and ovarian cancer. Dr. Slomovitzs is a Gynecologic Oncologist at Broward Health and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies.
Highlights
a. Asbestos comprises a family of small silicate fibers that are found in nature.
b. Asbestos is known to cause different types of cancer.
c. The causal association between asbestos and ovarian cancer is weak and inconsistent
d. Peritoneal mesothelioma is histologically similar to ovarian cancer and pathologic confirmation of diagnosis is required before causal assumptions are made

Ovarian Sex Cord Stromal Tumors with Mona El-Bahrawy

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Mona El-Bahrawyto discuss ovarian sex cord stromal tumors. Dr. El-Bahrawy is the lead author of “Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management" (https://ijgc.bmj.com/content/early/2021/01/07/ijgc-2020-002018), which is the Lead Article of IJGC’s February 2021 issue.
Dr. El-Bahrawy is Professor of Practice in Histopathology at Imperial College London, United Kingdom, and Professor of Pathology at the University of Alexandria, Egypt, and President of the Egyptian Committee for Pathology Training. She specializes in Gynaecological Surgical Pathology with special interest in Gynaecological Tumour Pathology.
Highlights:
- Ovarian sex cord stromal tumours are rare tumours that include benign and malignant variants.
- They are broadly classified into three categories, which include pure stromal tumors, pure sex cord tumors and mixed sex cord stromal tumors.
- Some tumor types harbor hallmark mutations, such as FOXL-2 mutations detected in the majority of adult granulosa cell tumors.
- Surgery is the main treatment modality for sex cord stromal tumors with some role for chemotherapy and hormonal therapy in advanced and recurrent tumors.
- There is potential for the identification of therapeutic targets and development of targeted therapy for these tumors.

Reviewing the January Issue with Sadie Jones and Navya Nair (English Version)

In this issue of the IJGC Podcast, Editorial Fellows Sadie Jones and Navya Nair discuss the contents of the January issue of IJGC.

Role of Trastuzumab in Uterine Papillary Serous Tumors with Amanda Fader

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Amanda Fader to discuss the role of trastuzumab in uterine papillary serous tumors. Dr. Fader is an Associate Professor of Gynecology and Obstetrics, Vice Chair of Gynecologic Surgical Operations and Director of the Center for Rare Gynecologic Cancers at Johns Hopkins School of Medicine. She is recognized internationally as a rare uterine and ovarian cancer expert and is an active member of NRG Oncology and helps develop and co-lead innovative gynecologic cancer clinical trials.
Highlights:
• Uterine serous carcinoma (USC) is a biologically aggressive endometrial cancer subtype that accounts for a disproportionately high rate of endometrial cancer-related deaths.
• 25-30% of women with both early and advanced stage USC will have HER2 positive tumors.
• Molecularly-based therapeutic approaches in USC are increasing.
• Trastuzumab, an anti-HER2 therapy, in combination with platinum/taxane-based chemotherapy improves survival outcomes for women with HER2 positive USC.
• A randomized, Phase III cooperative group study is planned to study additional anti-HER2 therapies in women with all stages of USC.

100th Podcast: Conversaciones con el Editor-en-Jefe

Para celebrar el podcast número 100 de la revista IJGC, el Comité Editorial propuso entrevistar en español a nuestro Editor-en-Jefe , el Dr. Pedro Ramírez. El Dr. Luis Chiva, Video-Editor de nuestra revista y miembro del consejo de ESGO realizó recientemente esta tarea. En este encuentro tan especial, el Dr. Pedro Ramirez nos cuenta muchos detalles que revelan cuales son los sueños que desearía que se hicieran realidad en un futuro proximo en nuestra revista

100th Podcast: Conversations with the Editor-in-Chief

In honor of the International Journal of Gynecological Cancer’s 100th podcast, IJGC’s Editor-in-Chief, Dr. Pedro Ramirez, is interviewed by IGCS President and IJGC Editorial Board Member Dr. Robert Coleman to discuss the experiences of the Editor-in-Chief.

SENTOR Study: SLN in High-Risk Endometrial Cancer with Sarah Ferguson

Dr. Ferguson is a Professor in the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Toronto and a member of the Division of Gynecologic Oncology at University Health Network/Sinai Health Systems. She is the Director of Research for the Division of Gynecologic Oncology at Princess Margaret Cancer. Dr. Ferguson completed her residency in Obstetrics and Gynecology at University of Toronto and a fellowship at Memorial Sloan-Kettering Cancer Centre in Gynecologic Oncology. Current research program includes prospective surgical trials in cervical and endometrial cancer, evaluation of patient reported outcomes and molecular characterization of endometrial cancer.
Highlights:
+ Diagnostic accuracy of SLN technique is excellent in high grade endometrial cancer – high sensitivity (low false negative rate), high NPV , DR and bilaterality rate
+ Based on this is a viable option to surgical staging in this population (clinical stage 1, high grade endometrial cancer)
+ High proportion (26%) of node positive would be missed if SLN technique was not performed

ESGO-ESTRO-ESP Endometrial Cancer Guidelines with Nicole Concin

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Nicole Concin to discuss the ESGO-ESTRO-ESP Endometrial Cancer Guidelines (https://ijgc.bmj.com/content/early/2020/12/18/ijgc-2020-002230)

Options of Urinary Diversion in Gynecologic Oncology with Carlos Martinez-Gomez

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Carlos Martinez-Gomez to discuss TOPIC. Dr. Martinez-Gomez is an author of the Lead Article for IJGC’s January 2021 issue, “Urinary diversion after pelvic exenteration for gynecologic malignancies” (https://ijgc.bmj.com/content/early/2020/11/22/ijgc-2020-002015). Dr. Martinez-Gomez is a gynecologist oncologist at Institut Universitaire du Cancer de Toulouse, France, from 2016, where he performed the ESGO fellowship program under the supervision of Drs. Gwénaël Ferron and Alejandra Martinez. His areas of interest are immunology of cervical and ovarian neoplasms, advanced ovarian cancer, reconstructive surgery after pelvic exenteration, and surgical teaching.
Highlights:
• Pelvic exenteration is a demanding surgery requiring mastery of organ removal combined with functional reconstruction
• Pelvic exenteration should be performed in high-volume referral institutions by well-trained multidisciplinary teams
• Incontinent diversion represents a good option for unfit patients or those refusing the constraints entailed by continent diversions (self-catheterization, postoperative learning, engagement)
• Postoperative complications of both types of reconstruction are comparable, but the quality of life issues would seem to support continent diversions in young and fit patients
• Continent and non-contingent techniques should be offered to patients, with a final decision based on their preferences